Purpose: In our previous prospective randomized trial, external stent group showed higher rate of clinically relevant postoperative pancreatic fistula (POPF) compared with internal stent group in performing pancreaticojejunal anastomosis after pancreatoduodenectomy (PD). Thus, the purpose of this study was to determine the most appropriate pancreatic drainage method by investigating differences in long-term clinical outcome related with stent between external and internal pancreatic stent groups after postoperative 12 months. 
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Introduction
Pancreaticoduodenectomy (PD) is performed for a variety of benign or malignant conditions of the periampullary region. Despite the marked reduction in mortality rates to < 5% in many institutions around the world, postoperative pancreatic fistula (POPF) still occurs in 5% to 40% after PD and may cause intra-abdominal abscess, pseudoaneurysmal bleeding, and postoperative mortality by autolytic activity of pancreatic juice. [1] [2] [3] How to best prevent POPF after PD is the most challenging issue that lacks consensus. There have been many attempts to reduce the incidence of POPF by numerous modalities, such as technical variation of reconstruction, somatostatin analogues, pancreatic stenting, and pancreatic drainage. 4 Although many surgeons have used two types of pancreatic ductal stent, external or internal for pancreaticojejunal anastomosis, the outcomes of external and internal stenting trials are often discordant, [5] [6] [7] [8] [9] and definitive evidence regarding the optimal surgical technique to reduce POPF rates is still lacking.
Therefore, previously, multicenter, parallel group, prospective randomized trial was performed to determine the most appropriate pancreatic stenting method by investigating differences in early outcomes between external and internal stenting after PD. 10 328 patients enrolled from 4 tertiary referral hospitals were randomized to external (n=164) or internal (n=164) stent groups and underwent elective PD or pylorus-preserving PD (PPPD) with duct-to-mucosa pancreaticojejunostomy. The external stent group showed higher rate (24.4%) of clinically relevant postoperative pancreatic fistula (POPF) compared with internal stent group (18.9%; risk difference, 5.5%; 90% confidence interval, 2.0% to 13.0%). Although the degree of complications was mild, stent-related complications, including stent obstruction, transient peritonitis, and pancreatitis, occurred in the external stent group. Therefore, this previous trial demonstrated that internal stents seem to be superior to external stents in terms of early clinical outcome and convenient postoperative drain management. This short-term follow-up study has been ongoing with respect to secondary endpoints, including pancreatic function, remnant pancreatic volume, long-term complications, and quality of life 1 years after PD.
Thus, in view of the importance of long-term follow-up data, we here report on 1 year follow-up data of this trial to make a final decision for the most appropriate pancreatic drainage method.
Patients and Study Design
From August 2010 to January 2014, total 213 patients who underwent elective PD or PPPD with duct-to-mucosa pancreaticojejunostomy at Seoul National University Hospital, among patients enrolled in the previous randomized, controlled, parallel-group, equivalence trial (NCT01023594) conducted to test the hypothesis that the rates of POPF after PD is similar with external and internal stenting, were enrolled in this prospective randomized controlled trial for analysis of long-term clinical outcome. The study complied with the Declaration of Helsinki and was approved and overseen by the institutional review board.
Inclusion and Exclusion Criteria
In our previous study, patients were included if they (1) were 20 to 85 years of age; (2) had no history of previous chemotherapy, radiotherapy, or abdominal surgery; (3) had no severe comorbidities such as liver cirrhosis or end stage renal disease; and (4) provided written informed consent. Patients found to have too small (< 1 mm) or too large (> 5 mm) pancreatic ducts were excluded.
In this study, patients were included if they have been taken follow-up and evaluated via outpatient clinic without a history of other abdominal surgery for 12 months after surgery at Seoul National University Hospital.
Surgical Procedures and Perioperative Management
PD or PPPD was performed according to the individual surgeon. Pancreaticojejunostomy was performed in an end-to-side, duct-to-mucosal, two-layer manner. A 4-10 Fr silastic polyethylene tube was inserted externally or internally into the pancreatic duct as a stent according to random allocation. In the internal stent group, 3 cm of the distal side of the stent was placed in the jejunum. In the external stent group, the catheter exited via a small enterotomy 10~15 cm below the anastomosis, and was externalized through a stab incision in the anterior abdominal wall.
Fibrin glue was applied during every pancreaticojejunostomy. One to three Jackson-Pratt drains were routinely placed anterior and posterior to the pancreaticojejunostomy.
Both the aspect and volume of drains were recorded daily. The serum and drain fluid amylase levels were measured on postoperative days 1, 3, 5, 7, and 10. A contrast computed tomography scan was performed on day 5-7 to detect any complications including POPF, to establish the intra-abdominal extent of the fistula, and to decide on the best management strategy. The peripancreatic drains were then removed if there was no evidence of leakage. Early clinical outcomes of both groups were evaluated and analysed during 6 weeks after the operation at which the external stent was removed in outpatient clinic, including the rate of clinically relevant POPF occurrence, overall complications, and risk factors for clinically relevant POPF.
Study Endpoints
The primary endpoint of this study was long-term complications, including stent-related complications and pancreatic duct size change. The secondary endpoint was the evaluation of the pancreatic function, remnant pancreatic volume, and quality of life at 1 year after the operation. 
Endocrine Function Evaluation
Exocrine Function Evaluation
Exocrine function was evaluated by measuring levels of stool elastase, which is a simple diagnostic test that can be performed on a random stool sample. The stool elastase test is an enzyme-linked immunosorbent assay (ELISA), which uses antibodies against human pancreatic elastase. Human elastase-1 is remarkably stable and is found in the stool in about a six fold concentration as compared with pancreatic juice, thereby stool elastase reflects the secretory capacity of the pancreas. 12 An elastase value < 100 mcg/g of stool is indicative of severe exocrine pancreatic insufficiency (EPI), while levels from 100-200 are described as suggestive of mild EPI. Stool elastase level was measured on Preoperative day, postoperative days 7, and 1 year after the operation.
Pancreas Volumetry
Late-arterial 3-mm-thick three-phase contrast-enhanced axial and coronal computed 
Quality of Life
Quality of life (QoL) was measured between 1 and 2 weeks after operation (immediate postoperation), then at 12 months, using the core cancer QoL assessment module (the EORTC QLQ-C30) and a pancreatic cancer-specific module (the EORTC QLQ-PAN26) developed by the European Organization for Research and Treatment of Cancer (EORTC) QoL study group.
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Questionnaires were self-reported by patients, but a trained nurse assisted anyone unable to do this. Raw data was converted to a 0 to 100 scale for standardization of the raw scores, as recommended in the EORTC QLQ-C30 scoring manual.
Statistical Analysis
Results are presented as mean ± standard error of the mean. Nominal data were compared using χ 2 test or Fisher's exact test and continuous variables using Student t tests and the MannWhitney U test. The change in remnant pancreatic volume for a year after the operation is presented as a box-and-whisker plot. All statistical analyses were performed using SPSS, version 21.0 (SPSS Inc., Chicago, IL), with 2-sided P values less than 0.05 considered statistically significant.
Patient Enrollment and Demographic Findings
Between August 2010 and January 2014, a total of 213 patients were enrolled in this long-term study. Of 213 patients, 116 were the external stent group and 97 were the internal stent group.
After enrollment, 28 patients were excluded because of (1) death (n = 15), (2) loss of follow-up (n = 10), or (3) a history of other abdominal surgery for 12 months after PD (n = 3). We therefore evaluated a total of 185 patients, 97 in the external stent group and 88 in the internal stent group (Fig. 2 ).
There were no significant differences in mean age, sex distribution, operative indication, operative method, pancreatic texture, pancreatic stent size, estimated blood loss, and operation time between 2 groups (Table 1) . Although the mean postoperative pancreatic duct size in the internal stent group was significantly larger compared to that in the external stent group (P = 0.003), those at postoperative 12 months were comparable (P = 0.806). Table 2 *Postoperative outcomes were evaluated and analyzed during 6 weeks after the operation at which the external stent was removed in outpatient clinic. †Transient peritonitis (2 patients), stent obstruction (2) and pancreatitis (1). PPH, postpancreatectomy hemorrhage; POPF, postoperative pancreatic fistula; ICU, intensive care unit.
Late Complications
The overall rate of late complication during follow-up period since postoperative 6 weeks was comparable between two groups (Table 3 ).
All follow-up CT scans of patients in the internal stent group were reviewed to determine in consensus the stent migration. Of 88 patients, the stent was completely detached from the pancreaticojejunostomy at postoperative 3 months in 57 (64.8%) and 6 months in 22 (25.0%).
The stent of 9 patients (10.2%) was not detached during follow-up period. After detachment of the stent, follow-up CT scans showed abnormal stent migration in 9 patients (10.2%), not passing spontaneously into the small intestine and uneventfully through the rectum. The abnormally migrated stents were most commonly located in the hepaticojejunostomy anastomosis (n = 4, 4.5%), followed by the intrahepatic duct (n = 3, 3.4%) and the remnant pancreatic duct (n = 2, 2.3%) (Fig. 3) . However, there were no abnormally migrated stentinduced complications identified during follow-up period. 
Change in Pancreatic Volume and Duct Size
There was no significant difference in the atrophy rate of remnant pancreas between 2 groups (P = 0.221). The median percentage of change in remnant pancreatic volume for 12 months was 45.2% (range 3.2-82.8 %) in the external stent group and 46.6 (range 6.2-75.1 %) in the internal stent group (Fig. 4) .
Although the mean postoperative pancreatic duct size was significantly different between 2 groups (2.58±0.51 vs. 2.89±0.83 mm, P = 0.003), the pancreatic duct size at postoperative 12 months was comparable (3.24±1.40 vs. 3.30±1.46 mm, P = 0.806) ( Table 1 ). The pancreatic ductal dilatation at postoperative 12 months occurred 59.8% in the external stent group and 55.7%
in the internal stent group (P = 0.496) ( Table 5 ). 
Pancreatic Function and Quality of Life
Patients with preoperative normal glucose were 48/97 in the external stent group and 50/88 in the internal stent group. Of the 48 patients in the external stent group, 34 (70.8%) developed endocrine functional impairment, including 27 (56.2%) who developed IFG and 7 (14.6%) who developed overt DM (Fig. 5) . Of the 50 patients in the internal stent group, 20 (40.0%) developed IFG and 4 (8.0%) developed DM at postoperative 12 months. There was no significant difference in the rate of new-onset DM for 1 year after the operation between 2 groups (P = 0.066).
The stool elastase level of all the patients at postoperative days 7 was lower by a value of severe EPI. Although the stool elastase level was significantly lower in the external stent group than in the internal stent group due to an externalization of the pancreatic juice through the external stent after the operation (38.3±42.0 vs. 62.6±69.9 mcg/g of stool, P = 0.039), there was no significant difference in the stool elastase level between 2 groups at 1 year after the operation (Table 1) .
Global health status, other functional scales, and pancreatic cancer-specific scales showed similar patterns of change between 2 groups in both immediate postoperation and postoperative 12 months (Table 7 , 8, Fig. 6, 7) . 
Discussion
Stent placement across the PJ following PD may be useful for the diversion of pancreatic juice from the pancreatic anastomotic site, decompression of the remnant pancreas, and maintaining patency of the main pancreatic duct. However, the benefits remain controversial due to a lack of data. Although several RCTs, observational case series, 3, 15, 16 and meta-analyses 5, [6] [7] [8] 14 have demonstrated reduced POPF rates with the use of pancreatic stents compared with no stents after PD, previous reports comparing external and internal pancreatic stents are very limited. In previous 2 RCT comparing between external and internal stents, authors reported similar complication rates, including those of POPF. 17, 18 The retrospective study, comparing outcomes between external (n = 37) and internal (n = 37) stents, demonstrated the same POPF rate (5.4%) in both group, and therefore recommended the selective use of stents according to individual characteristics such as the presence of ampullary tumors or small pancreatic ducts (< 2 mm).
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This study is the first report to evaluate long-term clinical outcomes of external and internal stenting as an ongoing study with respect to secondary endpoints of previous short-term trial for determining the most appropriate pancreatic drainage method after PD.
This present RCT was designed to examine the hypothesis that long-term outcomes of external and internal pancreatic stenting could be equal, following an analysis of early outcomes with the POPF rates between 2 groups. In our previous trial, the external stent group showed a higher rate (24.4%) of clinically relevant POPF compared with the internal stent group (18.9%; risk difference, 5.5%; 90% confidence interval, 2.0% to 13.0%). Other postoperative outcomes were comparable between the two groups. In this long-term follow-up study, there were no significant differences in late complications, change in pancreatic volume and duct size, pancreatic endocrine and exocrine function, or quality of life between 2 groups. One of the most common concern about the stent insertion in PD is the stent-induced complication. Five stent-related complications occurred in the external stent group during short-term follow-up period, including transient peritonitis (in 2 patients), stent obstructions (in 2 patients), and pancreatitis (in 1 patient). The removal of external stents is potentially hazardous and obstruction or kinking of the external stent may lead to further complications. The incidence of abnormal stent migration in the internal stent group was 10.2% (9 of 88), including the hepaticojejunostomy anastomosis (4.5%), intrahepatic duct (3.4%), and the remnant pancreatic duct (2.3%). Even though 15 patients (17.0%) with the stent located in jejunal afferent limb was not included in the incidence, the stents may migrate to abnormal areas of the body or penetrate adjacent jejunal wall. Many previous studies reported that the incidence of stent migration into the bile ducts was 7-16.8%
after PD with the internal stent. 20, 21 In addition, pancreatic and bile duct stents have been reported to cause ductal inflammation and fibrosis, eventually leading to ductal stricture, chronic pancreatitis, and cholangitis. Even though there were no abnormally migrated stentinduced complications identified during follow-up period, it may cause unwanted results.
Closed follow-up via out-patient clinic for these patients will be needed.
Another important concern during an analysis of long-term outcomes was about change in pancreatic volume and duct size according to the timing of stent detachment, especially in the internal stent group. In computed tomography (CT) scans performed postoperatively every 3 months from each patient, there was no significant difference in the atrophy rate of the remnant pancreas according to the detachment time of internal stents (P = 0.655) ( Table 4 ). In addition, the pancreatic ductal dilatation or stricture rates were comparable between groups divided by the timing of stent detachment (P = 0.523) ( Table 5, 6 ).
There were some limitations to our study. First, our previous RCT was multicenter trial, however, this study was limited by a single-center study where all of the operations were performed by 3 hepatobiliary surgeons. It is due to many cases of follow-up loss or no standardization of routine follow-up via outpatient clinic by 4 tertiary referral hospitals, and may cause a selection bias in an analysis of long-term follow-up data. Second, the follow-up duration for evaluation of long-term clinical outcomes after PD was relatively short. More than 2 years after PD may be required for identification of stent-induced complications and nutritional index.
In conclusion, we discovered comparable long-term outcomes according to external and internal pancreatic stent use after PD. Internal stents may be preferred in terms of early safety and convenient postoperative drain management. Surgeons who selected the internal stent according to their preference have to be concerned about internal stent-induced complications following abnormal migration. 
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